EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 317 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 ESMO Award for Immuno-Oncology 2025 Recipient Announced November 4, 2025 For Some Kids with Brain Cancer, Targeted Therapy is Better than... June 29, 2022 ASCO 2023 roundup: Blood tests, drugs and exercise June 12, 2023 Load more HOT NEWS TMB Consortium Develops a TMB Calibration Tool FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell... “That is what I dream”: India’s journey to rolling out the... What’s happened to cancer clinical trials during the COVID-19 pandemic?
